Recent innovations in antibody engineering have resulted in novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and other bi- and trispecific antibody designs ...

To Oncology, and Beyond Macrogenics’s Dual-Affinity Re-Targeting (DART) antibody platform has produced several constructs that are now in clinical development in cancer indications, as are a ...

MacroGenics' DART technology enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens. DART therapeutics can accommodate ...

MGNX has one approved product, and focus is now on its DART platform for developing bispecific antibodies. The early data shows strong potential for flotetuzumab. Their pipeline looks highly ...

MacroGenics’s DART platform enables the design of dual specificity antibody-like therapeutic proteins that the firm claims can target multiple different epitopes using a single recombinant molecule.

They will use MacroGenics’ dual-affinity retargeting (DART) antibody platform. DART proteins can be used to redirect the body’s cell-destroying immune effector cells against tumors.

What's got so many drugmakers interested in MacroGenics' DART tech? The biotech hasn't even tested its antibodies from the platform in human studies. Yet the company's drugs can home in on two ...

Inc., the venture arm of Janssen's owner J&J, registers a big vote of confidence in Macrogenics' Dual-Affinity Re-Targeting (DART) platform at a time when bispecific antibodies are gaining traction in ...

The companies are combining forces to develop a range of drug candidates – based on MacroGenics’ Dual-Affinity Re-Targeting (DART) antibody platform – for a number of therapeutic areas such as ...

Polytherics Ltd., of London, said its Thiobridge antibody drug conjugate (ADC) collaboration with Macrogenics Inc., of Rockville, Md., has been extended following the successful outcome of a research ...